Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Trial of Liposomal Doxorubicin and Carboplatin in Patients With ER, PR, HER2 Negative Breast Cancer (TNBC)

NCT02315196 is registered in ClinicalTrials.gov with Rutgers, The State University of New Jersey as lead sponsor.

NCT NCT02315196
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02315196 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Trial of Liposomal Doxorubicin and Carboplatin in Patients With ER, PR, HER2 Negative Breast Cancer (TNBC)
Lead sponsor
Rutgers, The State University of New Jersey
Phase
Phase 2
Overall status
Active, not recruiting
Start date
February 25, 2015
Completion date
July 31, 2041
Enrollment
62 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

estrogen receptor-negative breast cancer, her2-negative breast cancer, progesterone receptor-negative breast cancer, stage iia breast cancer, stage iib breast cancer, stage iiia breast cancer, stage iiib breast cancer, stage iiic breast cancer, triple-negative breast cancer